Scanogen is a molecular diagnostic company developing systems to read the biomolecular information of body fluids with the goal of improving health care. The Company has developed Single MOLecule Tethering (SMOLT), a proprietary technology for rapid and ultra-sensitive detection of biomolecules. The Company is using this technology to develop a simple-to-use and sample-to-answer diagnostic platform. Scanogen has received NIH grants totaling $9.5 million to develop its diagnostic assays and it is currently focused on two areas: Point-of-care diagnosis and bloodstream infection detection.

The company is located in Baltimore, Maryland. This is a privileged location to collaborate with Johns Hopkins University and with government agencies in Washington D.C (FDA, NIH, NIST).

Read Scanogen FCOI Policy.